MarketBeat
27 Sept 2026, 16:02 UTC · 22h ago
Verdict
Headline takes no side. We score XENE +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 67% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Xenon has filed a new drug application (NDA) for azetukalner to treat focal-onset seizures.
Newpublished 2026-09-27 mentioning September 2026 filing
So whatA standard 12-month review plus potential 3-month DEA scheduling pushes the earliest commercial launch to late 2027.
More positive than 93% of claims this week
Xenon has paused the X-NOVA3 major depressive disorder and X-CEED bipolar depression studies to evaluate dose escalation changes for tolerability.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Newpublished 2026-09-27 mentioning current pause
So whatThis delay pushes back the timeline for psychiatry data beyond the Q1 2027 X-NOVA2 readout.
More negative than 85% of claims this week
Xenon expects to produce unblinded data from the X-NOVA2 Phase 3 major depressive disorder study in the first quarter of 2027.
Newpublished 2026-09-27
More positive than 54% of claims this week
Xenon expects its pain candidates XEN1701 and XEN1120 to enter Phase 2 proof-of-concept studies in 2027.
Newpublished 2026-09-27
More positive than 45% of claims this week
Which stocks this story touches
More positive than 67% of ticker scores this week
Positive news regarding an NDA filing and strong efficacy data for azetukalner in epilepsy is partially offset by the pause of its psychiatry program to improve tolerability.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
8h ago
−1.8%
Price is moving against the score
$36.29 vs $36.94 close before publication (Sep 25) · not market-adjusted
XENE chart →
